May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
The VEGF R2 Inhibitor SU5416 Reduces Ischemia-Induced Retinopathy: A Novel Method to Quantitate Retinal Neovascularization
Author Affiliations & Notes
  • G.S. Robinson
    Ophthalmology, Pharmacia Corporation, Saint Louis, MO, United States
  • Footnotes
    Commercial Relationships  G.S. Robinson, Pharmacia Corporation E.
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 562. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      G.S. Robinson; The VEGF R2 Inhibitor SU5416 Reduces Ischemia-Induced Retinopathy: A Novel Method to Quantitate Retinal Neovascularization . Invest. Ophthalmol. Vis. Sci. 2003;44(13):562.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To develop a rapid and sensitive method to measure and statistically evaluate the effects of drug candidates in animal models of retinal disease. Methods: Oxygen-induced retinopathy was induced in C57BL/6J mice as described by Smith et al (Smith et al. 1994, IOVS 35, 101-111). From P12-P17 mixed litters of mice were treated subcutaneously (s.c.) with 25 mg/kg/day (N= 8), 50 mg/kg/day (N=8) SU5416, or vehicle (N=8). Mice were anesthetized and euthanized with cardiac perfusion of 4% paraformaldehyde, eyes enucleated, and fixed overnight in 4% paraformaldehyde before flat mounting retinas. Retinal flatmounts were stained with Hoeschst 33342 dye before coplanar optical analysis. An optical slice with a defined position with respect the ganglion cell layer was selected and Nearest Neighbor Deconvolution (NNDC) was performed to remove out-of-focus light from the in-focus image of vitreal endothelial nuclei. Results: We observed a 9.3 fold increase in vitreal endothelial nuclei in vehicle treated mice in hyperoxic conditions (401 +/- 64) as compared with normoxic controls (43 +/- 6). Treatment with SU5416 at 25 mg/kg/day and 50 mg/kg/day reduced retinal neovascularization by 8% (369 +/- 25) and 55% (181 +/- 15, p<0.05), respectively. These results matched published results as determined by endothelial cell counting. These results were obtained in a 2-3 day time period vs. a 3-6 week period necessary for endothelial cell counting. In addition, retinal hemorrhaging could be assessed and was reduced to normoxic control levels with both treatments of SU5416. Conclusions: We have developed a simple, fast and robust imaging procedure to quantitate retinal neovascularization and have used this model to analyze the effect of VEGF R2 inhibition on retinal neovascularization in a murine model of ROP. Our results confirm and expand published results obtained using the standard counting method. This new optical procedure provides a simple and accurate method to evaluate the effects of drug candidates in animal models of retinal disease with a more efficient use of resources.

Keywords: retinal neovascularization • diabetic retinopathy • retinopathy of prematurity 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×